<DOC>
	<DOCNO>NCT00820092</DOCNO>
	<brief_summary>1 . To investigate safety tolerability Xerecept follow 24-hour intravenous administration healthy Japanese healthy Japanese Caucasian subject 2 . To compare PK profile hCRF follow 24-hour intravenous Xerecept administration healthy Japanese Caucasian subject</brief_summary>
	<brief_title>Xerecept Intravenous Dose Escalation Japanese Caucasian Volunteers</brief_title>
	<detailed_description>none need</detailed_description>
	<criteria>Healthy male female Japanese subject citizens Japan Healthy male female Caucasian subject Age range 2045 year BMI &gt; 19 &lt; 27 kg/m square Female subject must pregnant time study use adequate birth control method , 4 week study Subjects must negative HCV HIV Subjects must negative urine test drug abuse alcohol screening Subjects must clinically significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Xerecept</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japanese versus Caucasians</keyword>
</DOC>